Enhancing Alzheimer’s Disease Diagnosis and Care by Focusing on Plasma Biomarkers for Identifying Mild Cognitive Impairment DOI
Rèmy Cardoso, Charlotte E. Teunissen, Catarina R. Oliveira

и другие.

Journal of Alzheimer s Disease, Год журнала: 2024, Номер 101(3), С. 731 - 734

Опубликована: Сен. 3, 2024

Biomarkers that accurately identify mild cognitive impairment (MCI) are of greater importance for Alzheimer's disease (AD) management and treatment. On the other hand, blood-based biomarkers not only more practical but also less invasive than common cerebrospinal fluid biomarkers. In their report in Journal Disease, Wang collaborators identified 67 upregulated 220 downregulated long noncoding RNAs (lncRNAs). They further demonstrated 4 these lncRNAs could discriminate MCI from cognitively healthy individuals. Apart significance as potential diagnosis, can offer additional information on cellular mechanisms AD pathology.

Язык: Английский

Brain lncRNA-mRNA co-expression regulatory networks and alcohol use disorder DOI Creative Commons

Ojong Tabi Ojong Besong,

Ji Sun Koo,

Huiping Zhang

и другие.

Genomics, Год журнала: 2024, Номер 116(5), С. 110928 - 110928

Опубликована: Авг. 26, 2024

Prolonged alcohol consumption can disturb the expression of both coding and noncoding genes in brain. These dysregulated may co-express modules interact within networks, consequently influencing susceptibility to developing use disorder (AUD). In present study, we performed an RNA-seq analysis long RNAs (lncRNAs) messenger (mRNAs) 192 postmortem tissue samples collected from eight brain regions (amygdala, caudate nucleus, cerebellum, hippocampus, nucleus accumbens, prefrontal cortex, putamen, ventral tegmental area) 12 AUD control subjects European ancestry. Applying limma-voom method, detected a total 57 lncRNAs 51 mRNAs exhibiting significant differential (P

Язык: Английский

Процитировано

1

Enhancing Alzheimer’s Disease Diagnosis and Care by Focusing on Plasma Biomarkers for Identifying Mild Cognitive Impairment DOI
Rèmy Cardoso, Charlotte E. Teunissen, Catarina R. Oliveira

и другие.

Journal of Alzheimer s Disease, Год журнала: 2024, Номер 101(3), С. 731 - 734

Опубликована: Сен. 3, 2024

Biomarkers that accurately identify mild cognitive impairment (MCI) are of greater importance for Alzheimer's disease (AD) management and treatment. On the other hand, blood-based biomarkers not only more practical but also less invasive than common cerebrospinal fluid biomarkers. In their report in Journal Disease, Wang collaborators identified 67 upregulated 220 downregulated long noncoding RNAs (lncRNAs). They further demonstrated 4 these lncRNAs could discriminate MCI from cognitively healthy individuals. Apart significance as potential diagnosis, can offer additional information on cellular mechanisms AD pathology.

Язык: Английский

Процитировано

0